Pinebridge Investments L.P. raised its stake in Celgene Corporation (NASDAQ:CELG) by 0.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,198 shares of the biopharmaceutical company’s stock after acquiring an additional 28 shares during the period. Pinebridge Investments L.P.’s holdings in Celgene Corporation were worth $2,494,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Neuberger Berman Group LLC grew its holdings in shares of Celgene Corporation by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC bought a new stake in shares of Celgene Corporation during the second quarter worth $3,616,000. Lincoln Capital Corp grew its holdings in shares of Celgene Corporation by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 185 shares during the last quarter. RiverPoint Capital Management LLC grew its holdings in shares of Celgene Corporation by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after purchasing an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of Celgene Corporation by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after purchasing an additional 54,210 shares during the last quarter. Institutional investors own 79.48% of the company’s stock.
Several analysts have recently commented on the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $175.00 target price on shares of Celgene Corporation in a report on Wednesday, August 9th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a report on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating and set a $162.00 target price on shares of Celgene Corporation in a report on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a report on Monday, July 31st. Finally, TheStreet cut Celgene Corporation from a “b-” rating to a “c+” rating in a report on Friday, November 17th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $139.57.
Celgene Corporation (NASDAQ CELG) opened at $104.50 on Friday. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $82,794.26, a PE ratio of 16.43, a price-to-earnings-growth ratio of 0.81 and a beta of 1.79.
Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the firm posted $1.58 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. equities research analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.
In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 in the last three months. Insiders own 0.95% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.